Company profile THRX
There is not enough data for Theseus Pharmaceuticals -pan-kit inhibitor to provide analysis
There is not enough data for Theseus Pharmaceuticals -pan-kit inhibitor to provide correlation calculation
There is not enough data for Theseus Pharmaceuticals -pan-kit inhibitor to provide analysis
After 39 days of this quarter the interest is at 328.0. Based on that we can calculate that during remaining 52 days it will total up to 765.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 439 | 592 34.9% QoQ | 476 -19.6% QoQ | 584 22.7% QoQ |
| 2020 | 629 43.3% YoY 7.7% QoQ | 450 -24.0% YoY -28.5% QoQ | 524 10.1% YoY 16.4% QoQ | 415 -28.9% YoY -20.8% QoQ |
| 2021 | 532 -15.4% YoY 28.2% QoQ | 536 19.1% YoY 0.8% QoQ | 656 25.2% YoY 22.4% QoQ | 570 37.3% YoY -13.1% QoQ |
| 2022 | 598 12.4% YoY 4.9% QoQ | 692 29.1% YoY 15.7% QoQ | 654 -0.3% YoY -5.5% QoQ | 565 -0.9% YoY -13.6% QoQ |
| 2023 | 777 29.9% YoY 37.5% QoQ | 870 25.7% YoY 12.0% QoQ | 572 -12.5% YoY -34.3% QoQ | 733 29.7% YoY 28.1% QoQ |
| 2024 | 328 -57.8% YoY -55.3% QoQ | - | - | - |
The average 5 years interest of targeted cancer therapy was 46.71 per week. The last year interest of targeted cancer therapy compared to the last 5 years has changed by 22.2%. The interest for targeted cancer therapy is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 25.4%.
After 39 days of this quarter the interest is at 58.0. Based on that we can calculate that during remaining 52 days it will total up to 135.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 74 | 32 -56.8% QoQ | 159 396.9% QoQ | 134 -15.7% QoQ |
| 2020 | 114 54.1% YoY -14.9% QoQ | 198 518.8% YoY 73.7% QoQ | 113 -28.9% YoY -42.9% QoQ | 129 -3.7% YoY 14.2% QoQ |
| 2021 | 174 52.6% YoY 34.9% QoQ | 89 -55.1% YoY -48.9% QoQ | 126 11.5% YoY 41.6% QoQ | 166 28.7% YoY 31.7% QoQ |
| 2022 | 173 -0.6% YoY 4.2% QoQ | 239 168.5% YoY 38.2% QoQ | 142 12.7% YoY -40.6% QoQ | 129 -22.3% YoY -9.2% QoQ |
| 2023 | 175 1.2% YoY 35.7% QoQ | 90 -62.3% YoY -48.6% QoQ | 209 47.2% YoY 132.2% QoQ | 143 10.9% YoY -31.6% QoQ |
| 2024 | 58 -66.9% YoY -59.4% QoQ | - | - | - |
The average 5 years interest of gastrointestinal stromal tumors was 10.98 per week. The last year interest of gastrointestinal stromal tumors compared to the last 5 years has changed by -4.01%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 22.27%.
There is not enough data for THE-630 to provide analysis
There is not enough data for THE-630 to provide correlation calculation
There is not enough data for THE-630 to provide analysis
There is not enough data for C797X-mediated resistance to provide analysis
There is not enough data for C797X-mediated resistance to provide correlation calculation
There is not enough data for C797X-mediated resistance to provide analysis
There is not enough data for osimertinib treatment to provide analysis
There is not enough data for osimertinib treatment to provide correlation calculation
There is not enough data for osimertinib treatment to provide analysis
After 39 days of this quarter the interest is at 260.0. Based on that we can calculate that during remaining 52 days it will total up to 607.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 333 | 435 30.6% QoQ | 399 -8.3% QoQ | 390 -2.3% QoQ |
| 2020 | 388 16.5% YoY -0.5% QoQ | 364 -16.3% YoY -6.2% QoQ | 448 12.3% YoY 23.1% QoQ | 369 -5.4% YoY -17.6% QoQ |
| 2021 | 417 7.5% YoY 13.0% QoQ | 475 30.5% YoY 13.9% QoQ | 369 -17.6% YoY -22.3% QoQ | 469 27.1% YoY 27.1% QoQ |
| 2022 | 376 -9.8% YoY -19.8% QoQ | 500 5.3% YoY 33.0% QoQ | 553 49.9% YoY 10.6% QoQ | 376 -19.8% YoY -32.0% QoQ |
| 2023 | 538 43.1% YoY 43.1% QoQ | 451 -9.8% YoY -16.2% QoQ | 536 -3.1% YoY 18.8% QoQ | 611 62.5% YoY 14.0% QoQ |
| 2024 | 260 -51.7% YoY -57.4% QoQ | - | - | - |
The average 5 years interest of non-small cell lung cancer was 34.7 per week. The last year interest of non-small cell lung cancer compared to the last 5 years has changed by 18.7%. The interest for non-small cell lung cancer is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 24.74%.
There is not enough data for drug resistance mutations to provide analysis
There is not enough data for drug resistance mutations to provide correlation calculation
There is not enough data for drug resistance mutations to provide analysis
There is not enough data for key driver oncogenes to provide analysis
There is not enough data for key driver oncogenes to provide correlation calculation
There is not enough data for key driver oncogenes to provide analysis